In future work, it will be important to address the relative contribution of these pathways to the protective effects of Mysm1‐deficiency in EuMyc B cell lymphoma, and this will provide insights into the possible effects of acquired p53 mutations on this protective activity. This evidence concerns the gene MYSM1 and B-cell non-Hodgkin lymphoma.